Kornimate/medical-research-clean huggingface dataset:
effect of polyglycolic acid mesh (neoveil) in thyroid cancer surgery

Conditions: Thyroid Gland Carcinoma; Thyroid Cancer; Thoracic Duct Leak

Summary: this study is a randomized controlled study to investigate the effect of "polyglycolic acid mesh sheet (neoveiltm)" on the thyroid cancer surgery.

thyroid cancer is a most common solid organ cancer in south korea, according to 2014 statistics from korea central cancer registry. the most important treatment of thyroid cancer is a surgery. principle of thyroid cancer surgery is cancer-involved thyroid gland resection and central/lateral compartment of neck node dissection. part of surgical complications associated with neck lymph node dissection are seroma and chyle leakage. incidence of seroma and chyle leakage have been reported as 4-5% and 1-7% in previous studies. currently, there's no effective agents to prevent these complications. "polyglycolic acid mesh sheet (neoveiltm)" is a tissue strengthening repair agent which is prevent air or fluid leakage. it's effects were proven in various surgical field - prevent air leakage in lung surgery, reduce pancreatic fistula in pancreas surgery and so on. however, there's no result in thyroid cancer surgery. this study will investigate the usability of neoveiltm in thyroid cancer surgery and have the effect of preventing seroma and chyle leakage.

Eligibility criteria:
inclusion criteria: * patients who are between 20 and 70 years of age * patients who agreed to the study * patients undergoing thyroidectomy and cervical node dissection for thyroid cancer * patients without perithyroidal organ infiltration or distant metastasis * before the operation, bilateral vocal cord movement was normal * patients without significant abnormal findings in laboratory tests before surgery exclusion criteria: * patients judged to be inadequate by the person in charge of clinical trial * aspirin, anti-platelet medication within 7 days of admission * uncontrolled hypertension, diabetes, chronic renal failure, coagulation disorders * cardiovascular disease (angina, heart failure, myocardial infarction, history of coronary artery disease, stroke, transient ischemic attack) * drug abuse and alcohol abuse * history of esophagus and airway diseases * patients who participated in other clinical trials within 30 days * patients who had previous history of neck irradiation or neck surgery * patients with a history of allergy to drugs * for women, pregnant and lactating patients

Keywords: thyroid cancer neoveil seroma chyle leakage
ultrasound acupuncture for oxaliplatin-induced peripheral neuropathy in colorectal cancer patients

Conditions: Colorectal Cancer Patients and Their Partners; Oxaliplatin-induced Peripheral Neuropathy

Summary: the current study was conducted to examine the effect of ultrasound acupuncture for oxaliplatin-induced peripheral neuropathy in colorectal cancer patients.

oxaliplatin is platinum-based chemotherapy most usually used for the treatment of metastatic colorectal cancer, this drug can produce a cumulative and dose-limiting distal sensory neuropathy affecting the majority of oxaliplatin-treated patients. despite intense investigation at the preclinical and clinical levels, no treatment can be suggested for the prevention of oipn. since acupuncture has proven effective in alleviating the severity of peripheral nerve neuropathy, as has ultrasound. this systematic review was conducted to test the ability of ultrasound acupuncture in decreasing neuropathy-related symptoms induced by oxaliplatin-based chemotherapies in colorectal cancer patients

Eligibility criteria:
inclusion criteria: - the subject selection was according to the following criteria: * adults their ages ranged from 20 to 70 years old. * receiving or have received chemotherapy treatment for colon or rectal cancer. * chemotherapy regimen included the agent oxaliplatin. * patients diagnosed with neuropathy by the oncologist. * both sexes. * no neuropathy prior to oxaliplatin treatment. * no documented or observable psychiatric or neurological disorders that would interfere with study participation (eg, dementia or psychosis) * stage ii, iii and iv colon or rectal cancer. * hands and feets were the most affected by cipn. * the first dose of oxaliplatin was from 4 months or more. exclusion criteria: * the potential participants were excluded in the following conditions: * another malignancy * patients with severe or unstable cardiorespiratory or musculoskeletal diseases that may influence the accuracy of quantitative sensory testing results. * participants who cannot remain on the same medications throughout the study period with minor dose adjustments allowed. * contraindications to therapeutic ultrasound including active cancer in region of hands or feet, presence of deep vein thrombosis, complete numbness in hands or feet (representing severe cipn), metal or plastic implantation * peripheral vascular disease in hands or feet.

Keywords: oxaliplatin peripheral neuropathy ultrasound acupuncture
ch1701 for prevention and treatment of radiation burns

Conditions: Cancer

Summary: a combined phase i\&ii, randomized, double-blind, placebo-controlled clinical trial to evaluate efficacy and safety for prevention and treatment of radiation therapy burn of ch1701


Eligibility criteria:
\*phase i: inclusion criteria: * healthy volunteers, aged 18 and older at the time of enrollment * voluntarily participate in the study by signing a consent form to participate in the study * ability to adhere to treatment according to researchers' assessment exclusion criteria: * subjects with other acute or chronic diseases need to be treated * it is not possible to comply with the research or studied drug treatment process in the opinion of the researcher * phase ii: inclusion criteria: * female patient, aged 18 to 60 years old * having been diagnosed with breast cancer with axillary lymph node metastasis, having radiation therapy for radiation therapy in the range of 45-50 gy for a period of 5-6 weeks * treatment can be started within 3 days of signing the consent to participate in the study * agree to voluntarily sign the consent form to participate in the study exclusion criteria: * the available skin lesions in the breast and chest and according to the researchers' judgment will affect the assessment of inflammation caused by radiation * the patient had radiation therapy before the breast area * history of connective tissue disorders * the patient is incapable of complying with the research procedures or is unable to ensure compliance with the study medication as assessed by the researcher * participate in other clinical trial studies within 1 month before joining this study
mri assessment of arrythmia ablation lesions

Conditions: Ventricular Tachycardia; Cardiac Arrhythmia

Summary: this study will evaluate the feasibility of visualization and characterization of arrhythmia ablation lesions by mri immediately following standard ablation techniques. the appearance of the ablation lesion will be correlated with clinical outcomes and risk of arrhythmia recurrence.

children's national heart institute (cnhi) with major contractual support from the national institutes of health / national heart, lung and blood institute has installed a combined x-ray / magnetic resonance imaging cardiac catheterization lab suite allowing for experts in the fields of cardiac mri, interventional cardiac mri and clinical pediatric interventional electrophysiology to work together to make substantial advancements in the development of novel techniques and applications to reach the goal of improved survival and care for the congenital heart disease population. the cnhi x-ray/mri suite will allow for streamlined transfer of patients from fluoroscopy directly to the mri scanner under the same sedation thereby allowing for immediate post procedure imaging and minimizing risk to the patient.

Eligibility criteria:
inclusion criteria: * written informed consent from any patient willing to participate who is undergoing an electrophysiology study with potential for arrhythmia ablation * written informed assent, if applicable exclusion criteria: * women who are pregnant * women who are nursing and who do not plan to discard breast milk for 24 hours * patients with a contraindication to mri scanning will be excluded. these contraindications include patients with the following devices: * central nervous system aneurysm clips * implanted neural stimulator * implanted cardiac pacemaker or defibrillator which are not mr safe or mr conditional according to the manufacturer * cochlear implant * ocular foreign body (e.g. metal shavings) * implanted insulin pump * metal shrapnel or bullet. * any intracardiac or intravascular device that is not mr safe or mr conditional according to the manufacturer based on both material and timing of device placement

Keywords: cardiac arrhythmia cardiac ablation congenital cardiac disease cardiac ablation lesions under magnetic resonance imaging
temporal interference for drug resistant epilepsy

Conditions: Drug Resistant Epilepsy

Summary: this single-center prospective study aims to investigate the treatment efficacy of temporal interference (ti) in drug-resistant epilepsy patients aged 6-60.

temporal interference (ti) technology is a novel non-invasive method for deep brain stimulation (dbs). by generating an overlapping electric field from safe currents, ti creates focused stimulation in targeted deep brain areas. this approach allows for the exploration of deep brain nuclei functions and has the potential to serve as a non-invasive alternative to traditional invasive dbs for clinical treatments. this study aims to investigate the treatment efficacy of ti deep brain stimulation by including drug-resistant patients aged 6-60. during and after ti stimulation, clinical and electrophysiology data will be recorded. clinical, imaging and electrophysiology data will be analyzed and processed to advance the treatment of drug-resistant epilepsy.

Eligibility criteria:
inclusion criteria: * participants are between the ages of 6 -60 years of age. * patients must be clinically evaluated as having drug resistant epilepsy. * persistence of disabling seizures at least 2 times per months or greater. * informed consent signed. exclusion criteria: * psychogenic non-epileptic seizures within 12 months; * presence of implanted electrical stimulation medical device anywhere in the body (e.g., pacemaker, spinal cord stimulator, responsive neurostimulation) or any metallic implants in the head (e.g., aneurysm clips, cochlear implants). note: vagal nerve stimulators are allowed if the parameter remains stable for at least 3 months prior to the screening visit; * risk factors that would put the participant at risk for intraoperative or postoperative bleeding. (e.g., coagulation abnormalities, etc.) or the need for chronic anticoagulation or antiplatelet aggregation medications; iq \< 55 or severe cognitive dysfunction, unable to complete the study; diagnosed with a progressive neurological disorder (including progressive rasmussen's encephalitis, etc.); * diagnosed with a severe neuropsychiatric disorder such as dementia, major depression (admission to a psychiatric specialty/hospital within 5 years or any suicidal or self-injurious tendencies), schizophrenia, or neurodegenerative disorders; * diagnosed with other serious physical disorders, internal diseases or severe abnormalities in liver or kidney function; pregnant, or planning to pregnant within 2 years; participation in another clinical study within 3 months; not suitable for enrollment as assessed by the multidisciplinary team of the center.

Keywords: temporal interference drug resistant epilepsy
the efficacy of nasal high flow oxygen therapy with rehabilitation in the patients with chronic respiratory failure

Conditions: Chronic Respiratory Failure; Nasal High Flow Therapy; Rehabilitation; Exercise Endurance

Summary: the purpose of this study is to compare the exercise endurance between oxygen therapy with rehabilitation and nasal high flow therapy with rehabilitation for the patients with chronic respiratory failure receiving long-term oxygen therapy.

in patients with chronic respiratory failure, pulmonary rehabilitation is recognized as an evidence-based treatment in improving exercise capacity, muscle strength, dyspnea, and quality of life. oxygen supplementation during exercise induced dose-dependent improvement in endurance and symptom perception in chronic obstructive pulmonary disease patients. recently, nasal high flow therapy which consists of high flow gas with an fio2 ranging from 0.21 to nearly 1.0 adjusted by an oxygen blender, brought to body temperature, and saturated with water through an in-line humidifier is available. the present study is randomised to compare the effect of exercise endurance between oxygen therapy with rehabilitation and nasal high flow therapy with rehabilitation for the patients with chronic respiratory failure receiving long-term oxygen therapy.

Eligibility criteria:
inclusion criteria: * subjects with chronic respiratory failure receiving long-term oxygen therapy for more than 3 months. exclusion criteria: * subjects with severe cardiovascular disease, diabetes, neurological disease, and renal failure. * subject who are unable to undergo rehabilitation.

Keywords: nasal high flow therapy rehabilitation exercise endurance
management of acute cardiogenic shock at the new brunswick heart centre

Conditions: Cardiogenic Shock

Summary: in atlantic canada, acute myocardial infarction occurs at a rate of 2.9 % of the population and is the most common cause of cardiogenic shock (cs). in many studies, acute myocardial infarction accounts for up to 80% of the patients with cs. while there are different methods of treating patients with cs, the rate of mortality has not significantly improved over the years and remains as high as 50%. recent studies have shown that a multi-modal, team-based approach can help improve patient outcomes; however, such a standardized approach is yet to be implemented in the new brunswick heart centre (nbhc). the study aims to understand the difference in outcomes between two groups of patients treated for cs: shock team versus non-shock team. this is a retrospective study of 168 patients using the data from nbhc registry and patient charts. the study duration is 1 year. the primary outcome is hospital survival. secondary outcomes include time from diagnosis to invasive monitoring and intervention. all data will be analyzed statistically between the two groups. the end goal of the study is to establish standard guidelines to treat cs patients and improve patient survival.


Eligibility criteria:
inclusion criteria: 1) any patient admitted to the ccu with a diagnosis of cs (scai groups c, d or e) at any point during their ccu care. exclusion criteria: 1) cs patients having scai groups a, b (this group was used only for preliminary analysis, hence this is the exclusion criteria for all final analyses).

Keywords: mortality outcomes ami shock team scai stage intervention iabp ecmo
avelumab program rollover study

Conditions: Solid Tumors

Summary: the main purpose of this study is to monitor the safety and tolerability of avelumab in participants with solid tumors who continue treatment with avelumab under the same treatment regimen as in the parent avelumab study.


Eligibility criteria:
inclusion criteria: * participants under enrollment and treatment in an avelumab clinical study under the sponsorship of emd serono research \& development institute, inc. / merck kgaa, darmstadt, germany * merck serono co., ltd (japan) * participants currently enrolled in an avelumab parent study and are on active treatment with avelumab or in long-term survival follow-up after treatment * participants on active treatment must agree to continue to use highly effective contraception (that is, methods with a failure rate of less than 1% per year) for both male and female participants if the risk of conception exists * other protocol defined inclusion criteria could apply. exclusion criteria: * participants who are pregnant or breastfeeding * participants still on active treatment: known hypersensitivity to any of the study intervention ingredients * participant has been enrolled in the comparator arm of avelumab parent study * participant has been withdrawn from avelumab parent study for any reason * any other reason that, in the opinion of the investigator, precludes the participant from participating in the study * other protocol defined exclusion criteria could apply.

Keywords: avelumab non-small cell lung cancer (nsclc) renal cell carcinoma (rcc) urothelial carcinoma (uc) ovarian cancer
resting metabolic rate testing in bariatric surgery patients

Conditions: Weight Loss; Bariatric Surgery Candidate

Summary: this study evaluates if measuring resting metabolic rate (the number of calories the body burns at rest) before surgery can help predict successful weight loss after surgery.

this is a prospective study enrolling patients from the baylor weight loss surgery center who have met all of the requirements to proceed with primary bariatric surgery. patients will undergo pre-operative and post-operative metabolic testing (6 months, and 1 year after surgery) using a portable calorimeter with eventual follow up of medical record at 5 years. data from up to 50 patients will be collected. the main objectives are to examine if the pre-operative resting metabolic rate can accurately predict successful weight loss after bariatric surgery and if it can be used to guide the selection of the type of bariatric surgery that would be most successful for the patient.

Eligibility criteria:
inclusion criteria: * all patients scheduled for a primary bariatric surgery * 18 years of age to no upper limit
feasibility and impact of online hiv/sti screening addressed to prep users in spain

Conditions: HIV; STI

Summary: non-blinded randomized controlled non-inferiority trial to evaluate the feasibility, acceptability and impact of an innovative internet-accessed hiv and stis screening intervention (téstate prep) addressed to gays, bisexuals and other men who have sex with men (gbmsm) and transgender women users of prep in spain as part of prep follow up.

the objectives of the study are 1) to design and implement an e-hiv/sti testing pilot intervention (téstate prep) to offer self-sampling kits to detect hiv, chlamydia trachomatis (ct), neisseria gonorrhoeae (ng) and treponema pallidum (tp) among gays, bisexuals and other men who have sex with men (gbmsm) and transgender women users of pre-exposure prophylaxis (prep) as part of prep follow up. 2) to evaluate if the pilot does not cause a reduction of the retention to prep follow up among the target population. 3) to analyze the capacity of the intervention to reduce the healthcare burden of the prep service. 4) to evaluate the acceptability of the intervention among prep users and healthcare workers of the prep services; and 5) to validate dried blood samples (dbs) for confirmation of tp infection and performing rpr to determine stage and activity of infection comparing with blood drawn by venous puncture. investigators will perform a non-blinded randomized controlled non-inferiority trial among prep users on follow up in one of the main prep services of spain. participants on the control arm will follow the usual follow up protocol with quarterly face-to-face visits where they will be tested for hiv and stis. participants in the experimental arm will alternate face-to-face meetings with online screening of hiv and stis. this project is based on the téstate project (pi17 00355). the website https://testate.org/ will include a module for online follow-up visits of participants on prep. participants of the experimental arm will register in the website and will receive self-sampling kits to their home to get tested for hiv, ct, ng and tp. participants will send the samples to the reference laboratory and check their results online. the investigators will compare the retention to follow up among prep users in the control and experimental arm and the healthcare burden in each group. the acceptability of the intervention among the prep users and healthcare workers will be assessed.

Eligibility criteria:
inclusion criteria: * ≥18 years of age * gbmsm or transgender women * prep users with more than 1 year of follow up in the collaborating center (the centre for international health and infectious diseases drassanes vall d'hebron (barcelona)) * not having altered renal function * resident in spain exclusion criteria: * not able to read in spanish * not able to give their consent

Keywords: hiv sti pre-exposure prophylaxis (prep) e-sti self-sampling screening ict
a randomized trial for suicidal patients

Conditions: Suicidal Ideation; Attempted Suicide; Suicide

Summary: although suicide risk is highly prevalent among the patient population in mental health care, remarkably little research exists on effective treatments. among a small set of novel approaches, cams is particularly promising. the investigators compare cams to tau in a randomized controlled trial at four departments in vestre viken hospital trust, hypothesizing cams to be the superior approach. primary outcome measures are suicidal ideation and suicide attempts, with secondary outcome measures including general symptoms of mental health problems. changes in the outcome measures are compared between the two groups from baseline to 6 and 12 months after patients are included in the study. the study has the potential to impact the science of treating suicidal individuals and it could benefit the general public by establishing cams as an effective clinical approach for rapidly reducing suicide risk.


Eligibility criteria:
inclusion criteria: * significant suicide ideation on beck's scale for suicide ideation (score 13 and above). informed consent to participate. exclusion criteria: * active psychosis, cognitive or physical impairment or other problems that preclude the ability to understand the study procedures and provide informed consent, non-norwegian speaking subjects